Kubo Nobuo, Senda Michio, Ohsumi Yasunori, Sakamoto Setsu, Matsumoto Keiichi, Tashiro Manabu, Okamura Nobuyuki, Yanai Kazuhiko
Department of Otolaryngology, Kansai Medical University, Osaka, Japan.
Hum Psychopharmacol. 2011 Mar;26(2):133-9. doi: 10.1002/hup.1184.
We have evaluated the sedative properties of H1-antihistamines by using positron emission tomography (PET) and ¹¹C-doxepin. The purpose of the present study was to measure histamine H1 receptor occupancy (H1RO) of loratadine 10 mg in patients with allergic rhinitis and to compare this occupancy with that of d-chlorpheniramine 2 mg, a first-generation antihistamine. We also compared our PET findings with the proportional impairment ratio reported by McDonald et al.
The H1RO of loratadine 10 mg and d-chlorpheniramine 2 mg were evaluated in human brains in a double-blind and crossover design using ¹¹C-doxepin PET. Eleven young male patients with allergic rhinitis were examined by PET following oral single administration of loratadine 10 mg and d-chlorpheniramine 2 mg.
Loratadine 10 mg occupied 11.7 ± 19.5% of histamine H1 receptors in the cortex, whereas d-chlorpheniramine 2 mg occupied 53.0 ± 33.2% in the same area, suggesting a non-sedating property of loratadine at a dose of 10 mg. The H1RO values of loratadine and d-chlorpheniramine as well as those of previous studies were found to be significantly proportional to the proportional impairment ratio (r = 0.899).
Measurement of H1RO is a sensitive and absolute method to characterize the non-sedating property of drugs with H1 antagonistic activity.
我们通过正电子发射断层扫描(PET)和¹¹C-多塞平评估了H1抗组胺药的镇静特性。本研究的目的是测量10毫克氯雷他定在过敏性鼻炎患者中的组胺H1受体占有率(H1RO),并将该占有率与第一代抗组胺药2毫克右氯苯那敏的占有率进行比较。我们还将PET研究结果与McDonald等人报告的比例损伤率进行了比较。
采用¹¹C-多塞平PET,以双盲交叉设计评估10毫克氯雷他定和2毫克右氯苯那敏在人脑中的H1RO。11名患有过敏性鼻炎的年轻男性患者在口服单次给予10毫克氯雷他定和2毫克右氯苯那敏后接受PET检查。
10毫克氯雷他定占据皮质中组胺H1受体的11.7±19.5%,而2毫克右氯苯那敏在同一区域占据53.0±33.2%,这表明10毫克剂量的氯雷他定具有非镇静特性。氯雷他定和右氯苯那敏的H1RO值以及先前研究的值与比例损伤率显著相关(r = 0.899)。
测量H1RO是表征具有H1拮抗活性药物非镇静特性的一种灵敏且绝对的方法。